Theravance Biopharma (NASDAQ:TBPH) Issues Earnings Results, Meets Expectations

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings results on Monday. The biopharmaceutical company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07, Zacks reports. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%.

Theravance Biopharma Trading Down 0.0%

TBPH stock opened at $16.91 on Monday. Theravance Biopharma has a 12-month low of $11.20 and a 12-month high of $21.03. The stock has a market cap of $871.97 million, a price-to-earnings ratio of 7.69 and a beta of 0.19. The business’s 50-day moving average is $16.77 and its 200 day moving average is $16.91.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TBPH. BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Weiss Ratings raised Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 3rd. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their target price for the stock from $15.00 to $17.00 in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Eight analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.40.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares of the company’s stock, valued at $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider directly owned 9,174,453 shares in the company, valued at $155,965,701. This represents a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in Theravance Biopharma by 622.2% in the 4th quarter. Invesco Ltd. now owns 177,946 shares of the biopharmaceutical company’s stock valued at $3,329,000 after purchasing an additional 153,306 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth $705,000. Susquehanna Portfolio Strategies LLC raised its position in shares of Theravance Biopharma by 208.8% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 43,350 shares of the biopharmaceutical company’s stock valued at $811,000 after buying an additional 29,313 shares during the last quarter. Tang Capital Management LLC raised its position in shares of Theravance Biopharma by 32.9% in the fourth quarter. Tang Capital Management LLC now owns 351,252 shares of the biopharmaceutical company’s stock valued at $6,572,000 after buying an additional 86,944 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its stake in shares of Theravance Biopharma by 272.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 190,129 shares of the biopharmaceutical company’s stock worth $3,557,000 after buying an additional 139,081 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.